Loading...

MedXY News - clinical trial

MedXY AI/MedXY News/Tag: clinical trial

MedXY News

EnglishTag

clinical trial

172 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Automated Oxygen Control vs. Manual Care: Large-Scale Trial Finds No Difference in Clinical Outcomes for Extremely Preterm Infants

Automated Oxygen Control vs. Manual Care: Large-Scale Trial Finds No Difference in Clinical Outcomes for Extremely Preterm Infants

A multicenter randomized trial of 1,082 extremely preterm infants found that automated FiO2 control did not significantly reduce death or major morbidities compared to manual titration, though it remains a safe labor-saving tool for neonata

Section: Critical CareFeb 15, 2026

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints

This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic

Section: GastroenterologyFeb 4, 2026

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi

Section: Internal MedicineJan 25, 2026

Cast Immobilization is Non-inferior to Surgery for Unstable Weber B Ankle Fractures: Results from the SUPER-FIN Trial

Cast Immobilization is Non-inferior to Surgery for Unstable Weber B Ankle Fractures: Results from the SUPER-FIN Trial

The SUPER-FIN randomized trial reveals that cast immobilization is a viable, non-inferior alternative to surgery for unstable Weber B ankle fractures with a congruent mortise, leading to fewer complications and avoiding unnecessary hardware

Section: Emergency MedicineJan 21, 2026

Graded Sensorimotor Retraining for Chronic Low Back Pain: Clinical Efficacy and the Search for Treatment Responders

Graded Sensorimotor Retraining for Chronic Low Back Pain: Clinical Efficacy and the Search for Treatment Responders

The RESOLVE trial demonstrates that graded sensorimotor retraining provides modest pain relief for chronic low back pain. A secondary analysis reveals that these benefits are consistent across most patient subgroups, suggesting that the int

Section: NeurologyJan 17, 2026

Beyond the Hospital Walls: Can Prospective Audit and Feedback Solve the Discharge Antibiotic Dilemma?

Beyond the Hospital Walls: Can Prospective Audit and Feedback Solve the Discharge Antibiotic Dilemma?

A multicenter stepped-wedge trial reveals that while prospective audit and feedback by stewardship teams improves the quality of discharge antibiotic prescribing, it fails to reduce the overall volume or duration of therapy, highlighting th

Section: Infectious DiseasesJan 16, 2026

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial

A landmark Phase 3 trial establishes Intensity-Modulated Proton Therapy (IMPT) as a new standard for oropharyngeal cancer, demonstrating non-inferior progression-free survival, significantly improved overall survival, and a marked reduction

Section: newsJan 15, 2026

A Decadel Leap: TCX Regimen Outperforms Standard TAC in 10-Year Survival for High-Risk HER2-Negative Breast Cancer

A Decadel Leap: TCX Regimen Outperforms Standard TAC in 10-Year Survival for High-Risk HER2-Negative Breast Cancer

A 10-year randomized trial reveals that replacing anthracyclines with capecitabine (TCX) significantly improves overall survival and reduces toxicity compared to the standard TAC regimen in high-risk, HER2-negative breast cancer patients.

Section: newsJan 14, 2026

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis

The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its hi

Section: newsJan 13, 2026

$Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights$

Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights

This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory dise

Section: newsJan 13, 2026

Resveratrol and Type 2 Diabetes: Does the Red Wine Compound Really Control Blood Sugar?

Resveratrol and Type 2 Diabetes: Does the Red Wine Compound Really Control Blood Sugar?

A rigorous clinical trial reveals that five weeks of resveratrol supplementation does not improve blood sugar, GLP-1 levels, or gastric emptying in patients with type 2 diabetes.

Section: Diabetes & EndocrinologyJan 12, 2026

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.

Section: Clinical UpdatesJan 9, 2026

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation

A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumo

Section: GastroenterologyJan 9, 2026

Oral Zoliflodacin Proves Non-Inferior to Standard Dual Therapy for Gonorrhoea: A Milestone in Antimicrobial Resistance Management

Oral Zoliflodacin Proves Non-Inferior to Standard Dual Therapy for Gonorrhoea: A Milestone in Antimicrobial Resistance Management

This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.

Section: Infectious DiseasesJan 8, 2026

Adjunctive Omega-3 Supplementation Does Not Improve Pediatric Major Depressive Disorder: Insights from a Multi-Center Randomized Trial

Adjunctive Omega-3 Supplementation Does Not Improve Pediatric Major Depressive Disorder: Insights from a Multi-Center Randomized Trial

A multi-center randomized clinical trial involving 257 youths found that adjunctive omega-3 fatty acids (1.5 g/d) did not outperform placebo in treating moderate-to-severe pediatric major depressive disorder, despite high adherence and conc

Section: newsJan 6, 2026

Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial

Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial

The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a man

Section: newsJan 6, 2026

Immunotherapy Challenges in Metastatic Castration-Resistant Prostate Cancer: An In-Depth Analysis of the CheckMate 7DX Phase 3 Trial

Immunotherapy Challenges in Metastatic Castration-Resistant Prostate Cancer: An In-Depth Analysis of the CheckMate 7DX Phase 3 Trial

CheckMate 7DX demonstrates that adding nivolumab to docetaxel fails to improve survival outcomes in ARPI-pretreated, chemotherapy-naive mCRPC, while significantly increasing toxicity and treatment-related mortality.

Section: Clinical UpdatesJan 6, 2026

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients su

Section: Infectious DiseasesJan 2, 2026

Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT

Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT

The GRASS trial, a double-blind multi-centre RCT, found that adding 200 µg of selenium daily to standard antithyroid drug therapy does not increase remission rates or improve quality of life in patients with newly diagnosed Graves’ hyperthy

Section: Diabetes & EndocrinologyJan 1, 2026

Can Sertraline Reduce Repeat Violent Offenses? Insights from a Major Clinical Trial

Can Sertraline Reduce Repeat Violent Offenses? Insights from a Major Clinical Trial

A large, rigorous study found that sertraline, an antidepressant, does not significantly lower the risk of repeated violent crimes among impulsive offenders.

Section: newsDec 30, 2025

Prev 1 2 3 4 9 Next